SEC Form S-1 filed by Firefly Neuroscience Inc.
$AIFF
Computer Software: Prepackaged Software
Technology
Unavailable
Unavailable
Save time and jump to the most important pieces.
4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)
4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)
3 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)
SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)
SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)
SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)
A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc., released on May 5, 2025 at 8:00 am ET. Please note, the correct form of payment of the potential Evoke investors' earn-out is in Firefly's common stock. The complete corrected press release follows: Builds upon Firefly's recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company")
Builds upon Firefly's recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce its acquisition of Evoke Neuroscience, Inc. ("Evoke"), a medical device company developing and commercializing technologies to aid in the comprehensive assessment of brain health. The transaction marks another important step toward
KENMORE, N.Y., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announced that it has received total proceeds of $8,824,710 from the exercise of warrants to purchase 823,530 shares of the common stock of the Company, par value $0.0001 per share ("common stock"), at an exercise price of $6.83, and warrants to purchase 800,000 shares of commons stock, at an exercise price of $4.00, respectively. The warrants were issued pursuant to private placements that closed
10-Q - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)
8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)
8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)
TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of current director of the Board, Greg Lipschitz, as Executive Chairman, effective as of December 3, 2024. "I look forward to taking on a more active leadership role as Executive Chairman," said Greg Lipschitz, newly appointed Executive Chairman of Firefly. "I believe that Firefly is uniquely positioned at the intersection of artificial intelligence and brain health that I have l
TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of Stella Vnook, Ph.D. to its Board of Directors, effective as of August 19, 2024. Dr. Vnook will serve as Chairperson of the Nominating Committee. Dr. Vnook brings over 25 years of experience as a distinguished pharmaceutical executive, serial entrepreneur, CEO and founder of multiple biotech companies and visionary leader with a track record of success in biotechnology and life
Company successfully listed on Nasdaq under the symbol "AIFF" Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company's dual go-to-market strategy TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its financial results for the third quarter ended September 30, 2024, and provided a stockholder update. Firefly is dedicated to improving outcomes for people suffering wi